Colchicine for first-time deep-vein blood clots
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if adding colchicine (a medicine that reduces inflammation) to standard blood-thinning therapy can improve recovery from a first blood clot in the leg. It's for adults who just started treatment for a new deep-vein clot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with a first blood clot in the deep veins of your leg (above the knee) within the last 48 hours
- You have started or are about to start standard blood-thinner therapy
- You have not had a blood clot in the same leg before
- You are not currently taking colchicine or have a condition that requires it
- You do not have severe liver or kidney disease, active cancer expected to limit life to less than a year, or a history of certain gut conditions (like Crohn’s disease, ulcerative colitis, irritable bowel syndrome, or chronic diarrhea)
- You are not pregnant, breastfeeding, or using certain medicines that interact with colchicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
This trial tests if colchicine, a medicine used for gout, can reduce inflammation after a first deep vein thrombosis (blood clot in a large leg vein). It might help prevent long-term leg problems from the clot.
This study tests whether a medication called colchicine can help prevent amputation in people with severe leg blood flow problems who just had surgery or a catheter procedure to restore blood flow. Colchicine is an anti-inflammatory drug that may help protect the leg tissue after treatment.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial is testing whether a combination of two medicines—colchicine (an anti-inflammatory) and a low dose of rivaroxaban (a blood thinner)—can help prevent future heart attacks, strokes, or other blood vessel problems in people who recently had a stroke caused by a blood clot.
Hear when a new Post Thrombotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.